
Septerna Inc
SEPNHealthcare|Biotechnology|USA
$35.93
-1.91 (-5.05%)
Tangible Book
$8.43
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
71.73,
66.9,
68,
61.7,
99.22
],
"ebit_estimate": [
-97.77,
-142.66,
-184.1,
-251.93,
-283.69
],
"ebitda_estimate": [
-58,
-106,
-149,
null,
null
],
"net_income_estimate": [
-83.43,
-130.87,
-170.68,
-202,
-270.62
],
"per_share_eps_estimate": [
-1.76,
-2.5,
-2.87,
-3.84,
-4.15
],
"eps_nri_estimate": [
-1.76,
-2.53,
-2.89,
-3.39,
-4.12
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
8.06,
11.74,
8.82,
null,
null
],
"pretax_income_estimate": [
-83.29,
-130.87,
-170.68,
-241.83,
-270.62
],
"operating_cash_flow_per_share_estimate": [
-1.68,
-2.31,
-2.63,
null,
null
],
"roa_estimate": [
-7,
-14.6,
-21.4,
null,
null
],
"roe_estimate": [
-10.5,
-18.3,
-24.6,
null,
null
],
"gross_margin_estimate": [
100,
100,
100,
98,
94
],
"operating_cash_flow_estimate": [
-75.2,
-103.39,
-117.72,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
0
],
"long_term_growth_rate_mean": -38.56,
"long_term_revenue_growth_rate_mean": "11.70",
"future_per_share_eps_estimate_growth": -38.09,
"future_eps_nri_estimate_growth": -38.56,
"future_revenue_estimate_growth": 11.7,
"future_ebit_estimate_growth": -39.83,
"future_ebitda_estimate_growth": -35.18,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": -52.22,
"future_pretax_income_estimate_growth": -52.26,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": -38.25,
"future_roe_estimate_growth": -46.67,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712"
],
"revenue_estimate": [
15.71,
15.71,
17.79,
9,
9,
9,
9
],
"ebit_estimate": [
-26.61,
-28.85,
-30.59,
-55,
-58,
-60,
-66
],
"ebitda_estimate": [
-12,
-15,
-18,
null,
null,
null,
null
],
"net_income_estimate": [
-22.7,
-25.07,
-26.7,
-50,
-53,
-56,
-62
],
"per_share_eps_estimate": [
-0.47,
-0.52,
-0.53,
-0.82,
-0.81,
-0.9,
-0.92
],
"eps_nri_estimate": [
-0.46,
-0.51,
-0.53,
-0.82,
-0.81,
-0.9,
-0.92
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
-22.7,
-25.07,
-26.7,
-50,
-53,
-56,
-62
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
null,
null,
null
],
"long_term_growth_rate_mean": -38.56,
"long_term_revenue_growth_rate_mean": "11.70",
"future_per_share_eps_estimate_growth": -38.09,
"future_eps_nri_estimate_growth": -38.56,
"future_revenue_estimate_growth": 11.7,
"future_ebit_estimate_growth": -39.83,
"future_ebitda_estimate_growth": -35.18,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": -52.22,
"future_pretax_income_estimate_growth": -52.26,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": -38.25,
"future_roe_estimate_growth": -46.67,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}